NYSEAMERICAN:ARMP Armata Pharmaceuticals Q1 2026 Earnings Results & Report $3.86 +0.05 (+1.31%) Closing price 10/8/2026 04:10 PM EasternExtended Trading$3.86 0.00 (-0.13%) As of 07:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Armata Pharmaceuticals missed analyst earnings expectations but beat on revenue in its Q1 2026 results, released May 13, 2026. The company reported EPS of -$3.16 versus the -$0.38 consensus estimate, while revenue of $0.79 million topped the $0.74 million estimate by $0.05 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 13, 2026TimeBefore Market OpensConference Call8:00 AM ET Armata Pharmaceuticals EPS ResultsActual EPS-$3.16Consensus EPS -$0.38Beat/MissMissed by -$2.78One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersArmata Pharmaceuticals Revenue ResultsActual Revenue$0.79 millionExpected Revenue$0.74 millionBeat/MissBeat by +$49.00 thousandYoY Revenue GrowthN/AUpcoming EarningsArmata Pharmaceuticals' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Armata Pharmaceuticals Q1 2026 Earnings FAQ Did Armata Pharmaceuticals beat earnings estimates for Q1 2026? Armata Pharmaceuticals (NYSEAMERICAN:ARMP) reported earnings of -$3.16 per share for Q1 2026, missing the consensus estimate of -$0.38. The report was announced on Wednesday, May 13, 2026. What was Armata Pharmaceuticals' revenue for Q1 2026? Armata Pharmaceuticals reported revenue of $0.79 million for Q1 2026, against a consensus estimate of $0.74 million. When is Armata Pharmaceuticals' next earnings date? Armata Pharmaceuticals' next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Armata Pharmaceuticals on the company's earnings history page. Armata Pharmaceuticals Earnings HeadlinesArmata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United StatesOctober 7 at 7:00 AM | prnewswire.comJonesTrading Reaffirms Their Buy Rating on Armata Pharmaceuticals (ARMP)September 28, 2026 | theglobeandmail.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.October 9 at 1:00 AM | Profits Run (Ad)Armata Pharmaceuticals Receives Additional Non-Dilutive Funding To Support AP-SA02 Phase 3 DevelopmentSeptember 23, 2026 | marketscreener.comMArmata Gets $3.7M DoW Funding For AP-SA02 Phase 3 Development; Stock DownSeptember 23, 2026 | rttnews.comArmata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 DevelopmentSeptember 23, 2026 | prnewswire.comSee More Armata Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Armata Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Armata Pharmaceuticals and other key companies, straight to your email. Email Address About Armata PharmaceuticalsArmata Pharmaceuticals (NYSEAMERICAN:ARMP) is a clinical-stage biotechnology company focused on developing bacteriophage-based therapeutics to treat bacterial infections, including infections caused by antibiotic-resistant pathogens. Bacteriophages, or “phages,” are viruses that selectively target and destroy specific bacteria, offering a potential alternative or complement to conventional antibiotics. The company’s pipeline includes investigational phage therapies for serious respiratory and systemic infections. Its lead programs have targeted infections caused by Pseudomonas aeruginosa, including pulmonary infections associated with cystic fibrosis and other chronic lung conditions, as well as infections caused by Staphylococcus aureus. Armata is evaluating these candidates in clinical studies and continues to research phage compositions and manufacturing approaches designed to improve their therapeutic potential. Armata is headquartered in Marina del Rey, California, and conducts its development activities primarily in the United States. The company originated from C3J Therapeutics and adopted the Armata Pharmaceuticals name following its acquisition of C3J’s phage-therapy business. Todd R. Patrick serves as the company’s president and chief executive officer.View Armata Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Applied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueSkydance Just Became a Media Giant—With an $80 Billion Debt LoadConstellation Brands Beat Earnings, But Beer Demand Is Still a ProblemTesla's EV Delivery Beat Is In, So What Happens Now?BigBear.ai Is Heavily Shorted—and Its Fundamentals Are Starting to Change Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
